Skip to main content
The Globe and Mail
Get full access to globeandmail.com
Support quality journalism
Just $1.99 per week for the first 24weeks
Just $1.99 per week for the first 24weeks
The Globe and Mail
Support quality journalism
Get full access to globeandmail.com
Globe and Mail website displayed on various devices
Just$1.99
per week
for the first 24weeks

var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){console.log("scroll");var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))}pencilInit(".js-sub-pencil",!1);
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 72.95
Day High 75.40
Open:74.37
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Description
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Their portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

ValuEngine Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Gilead Canada Submits Supplemental New Drug Submission to Health Canada for Descovy® for HIV Pre-Exposure Prophylaxis
- CNW Group - Thu Apr 9, 7:00AM CDT
CNW Group - CMTX
Thu Apr 9, 7:00AM CDT
-- Submission supported by data from the DISCOVER trial, which evaluated the safety and efficacy of Descovy® compared to Truvada® in people at risk for sexually acquired HIV-1 infection --
Gilead Canada Submits Supplemental New Drug Submission to Health Canada for DESCOVY® for HIV Pre-Exposure Prophylaxis
- CNW Group - Thu Apr 9, 7:00AM CDT
CNW Group - CMTX
Thu Apr 9, 7:00AM CDT
-- Submission supported by data from the DISCOVER trial, which evaluated the safety and efficacy of Descovy® compared to Truvada® in people at risk for sexually acquired HIV-1 infection --
Prime Healthcare Participating in Program for Promising COVID-19 Treatment
- PR Newswire - Wed Apr 8, 1:16PM CDT
PR Newswire - CMTX
Wed Apr 8, 1:16PM CDT
One of the most promising treatments for COVID-19 is being made available through an expanded access program at Prime Healthcare's Saint Michael's Medical Center in Newark.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 64.41 +13.79% increase
on 03/16/20
Period Open:73.52
Price movement based on the high, low and last over the given period.
85.97 -14.75% decrease
on 03/19/20
-0.23 (-0.31%) decrease
since 03/09/20
3-Month 62.23 +17.77% increase
on 01/21/20
Period Open:65.84
Price movement based on the high, low and last over the given period.
85.97 -14.75% decrease
on 03/19/20
+7.45 (+11.32%) increase
since 01/09/20
52-Week 60.89 +20.36% increase
on 10/03/19
Period Open:66.09
Price movement based on the high, low and last over the given period.
85.97 -14.75% decrease
on 03/19/20
+7.20 (+10.89%) increase
since 04/09/19

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies